Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2184760 | 1.00 | HTR2A (0.54) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL5724349 | 0.90 | HTR2A (0.55) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5724347 | 0.89 | HTR2A (0.54) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL13396487 | 0.86 | CA1 (0.50) | HTR2ARAB9APOLBSMN1; SMN2HTT | |
| SCHEMBL29171050 | 0.85 | HTR2A (0.59) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL8247254 | 0.83 | HTR2A (0.60) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL12214491 | 0.82 | HTR2A (0.53) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL7275342 | 0.82 | HTR2A (0.53) | HTR2AIDO1RAB9APOLBSMN1; SMN2 | |
| SCHEMBL9782567 | 0.82 | IDO1 (0.56) | HTR2AIDO1RAB9AHTTALDH1A1 | |
| SCHEMBL9820376 | 0.82 | IDO1 (0.56) | HTR2AIDO1RAB9AHTTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024148237-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC INHIBITORS OF MYCOBACTERIA, INCLUDING M. TUBERCULOSIS | TRANA DISCOVERY, INC. (US) | 2024-07-11 | — | — | WO | disclosed |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | TRANA DISCOVERY, INC. (US) | 2019-06-11 | — | — | US | disclosed |
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2014-06-12 | — | — | US | disclosed |
| EP-2691542-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | Trana Discovery, Inc. (US) | 2014-02-05 | — | — | EP | disclosed |
| US-8431341-B2 | Compositions and methods for the identification of inhibitors of protein synthesis | TRANA DISCOVERY, INC. (US) | 2013-04-30 | — | — | US | disclosed |
| WO-2012135416-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2012-10-04 | — | — | WO | disclosed |
| US-8232378-B2 | Compositions and methods for the identification of inhibitors of protein synthesis | TRANA DISCOVERY, INC. (US) | 2012-07-31 | — | — | US | disclosed |
| US-20110229920-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2011-09-22 | — | — | US | disclosed |
| EP-2342339-A2 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | Trana Discovery, Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| WO-2010036795-A2 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | TRANA DISCOVERY, INC. (US) | 2010-04-01 | — | — | WO | disclosed |
| US-20100069260-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS | GUENTHER RICHARD H | 2010-03-18 | — | — | US | disclosed |
| US-7598040-B2 | Compositions and methods for the identification of inhibitors of protein synthesis | TRANA DISCOVERY, INC. (US) | 2009-10-06 | — | — | US | disclosed |
| US-20080199870-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS | TRANA DISCOVERY, INC. | 2008-08-21 | — | — | US | disclosed |
| WO-2008064304-A9 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS | TRANA DISCOVERY INC (US) | 2008-07-10 | — | — | WO | disclosed |
| WO-2008064304-A2 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS | TRANA DISCOVERY, INC. (US) | 2008-05-29 | — | — | WO | disclosed |
| US-4440682-A | Stereospecific synthesis of isocephalosporins and 2-oxa isocephalosporins | LABORATORIO FARMACEUTICO QUIMICO "LAFARQUIM, S.A." (ES) | 1984-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140163037-A1 | SCREENING METHODS FOR IDENTIFYING SPECIFIC STAPHYLOCOCCUS AUREUS INHIBITORS | NSUN3, RNGTT, TRMT1 | HTR2A 3280/4885IDO1 1786/4885RAB9A 2694/4885 |
| US-20100069260-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS | NSUN3, RNGTT, TARBP1 | HTR2A 4468/4885IDO1 3864/4885RAB9A 3795/4885 |
| US-10316371-B2 | Screening methods for identifying specific Staphylococcus aureus inhibitors | NSUN3, RNGTT, TRMT1 | HTR2A 3280/4885IDO1 1786/4885RAB9A 2694/4885 |
| US-20080199870-A1 | COMPOSITIONS AND METHODS FOR THE IDENTIFICATION OF INHIBITORS OF PROTEIN SYNTHESIS | NSUN3, RNGTT, TARBP1 | HTR2A 4468/4885IDO1 3864/4885RAB9A 3795/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.